Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atomoxetine, an inhibitor of, the presynaptic transporter of norepinephrine, was approved for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents and adults in the USA in 2002, and in Europe, first in the UK and then by mutual recognition in several countries during 2003 and 2004. Since that time, the use of atomoxetine has spread globally and extensive additional research has been conducted evaluating its efficacy and safety. OBJECTIVE: The objective of this review is to provide a summary of the available data on atomoxetine, with an emphasis on postmarketing clinical research, which is helping to clarify the role of this agent in ADHD pharmacotherapy. METHODS: Recent as well as long-term safety and efficacy data are reviewed, with an emphasis on comparison with long-acting psychostimulants, ADHD in special populations and in patients with psychiatric comorbidities. RESULTS/CONCLUSION: Atomoxetine is an effective acute and long-term pharmacotherapy for ADHD, and may play a particular role in the treatment of patients with comorbid disorders and those who have failed or are unable to tolerate stimulants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
ADHD Comorbidity Findings From the MTA Study: Comparing Comorbid Subgroups
JENSEN, P. S., HINSHAW, S. P., KRAEMER, H. C., LENORA, N., NEWCORN, J. H., ABIKOFF, H. B., MARCH, J. S., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00009 · Cited by 974 · cited 1×
“1 Oppositional defiant disorder Oppositional defiant disorder (ODD) occurs in 30 – 60% of patients with ADHD and often correlates with increased ADHD symptoms, overall ADHD severity and poorer treatment outcomes [37].”
BackgroundGreenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 2×
“1 Efficacy trials A series of more than a dozen double-blind, placebo-controlled (DBPC) studies have provided evidence of the safety and efficacy of atomoxetine for the treatment of ADHD in children, adolescents, and adults [20,23-27].”
BackgroundSelf-citationKelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 1×
“1 Efficacy trials A series of more than a dozen double-blind, placebo-controlled (DBPC) studies have provided evidence of the safety and efficacy of atomoxetine for the treatment of ADHD in children, adolescents, and adults [20,23-27].”
BackgroundNewcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336 · cited 2×
“The study’s investigators speculate that this provides evidence of differential response to treatment for some patients [30].”
BackgroundSelf-citationSpencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · cited 1×
“1 Efficacy trials A series of more than a dozen double-blind, placebo-controlled (DBPC) studies have provided evidence of the safety and efficacy of atomoxetine for the treatment of ADHD in children, adolescents, and adults [20,23-27].”
BackgroundSelf-citation
Cited by
Gillberg, C. (2010) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2010.06.002 · Cited by 742
Cunill, R., Castells, X., Tobias, A., & Capellà, D. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3473 · Cited by 70
A Double-Blind, Placebo-Controlled Study of Atomoxetine in Young Children With ADHD
Kratochvil, C. J., Vaughan, B. S., Stoner, J. A., Daughton, J. M., Lubberstedt, B. D., Murray, D. W., Chrisman, A. K., Faircloth, M. A., Itchon-Ramos, N. B., Kollins, S. H., et al. (2011) · Pediatrics · doi:10.1542/peds.2010-0825 · Cited by 70
Self-citationAre Eating Disorders Related to Attention Deficit/Hyperactivity Disorder?
Reinblatt, S. P. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0060-7 · Cited by 39
Gabriel, A., & Violato, C. (2011) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-011-0063-1 · Cited by 30
“It was demonstrated in recent studies that atomoxetine was not associated with QT interval prolongation, and that cardiovascular effects of atomoxetine were minimal (Spencer et al. 1998; Wernicke et al. 2003; Vaughan et al. 2009).”
Metadata
- Authors
- Vaughan, B., Fegert, J., & Kratochvil, C. J.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2009-02-25
- Volume
- 10
- Issue
- 4
- Pages
- 669-676
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2022125077
- Cited by
- 49
- References
- 22
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. https://app.cochat.ai/papers/10.1517/14656560902762873
- The paper
- Vaughan, B., Fegert, J., & Kratochvil, C. J. (2009). Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656560902762873
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.